Therapeutic developments in acute lymphoblastic leukemia

Amy MacKenzie, Margaret KasnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USAAbstract: The standard treatment of adult-onset acute lymphoblastic leukemia (ALL) is based on trials conducted 20&ndash;25 years ago and has remained largely unchanged since that...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	MacKenzie A, Kasner M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/f7dd595bd9334542af83b920fe83b3ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f7dd595bd9334542af83b920fe83b3ab
record_format	dspace
spelling	oai:doaj.org-article:f7dd595bd9334542af83b920fe83b3ab2021-12-02T05:35:32ZTherapeutic developments in acute lymphoblastic leukemia1179-9889https://doaj.org/article/f7dd595bd9334542af83b920fe83b3ab2012-11-01T00:00:00Zhttp://www.dovepress.com/therapeutic-developments-in-acute-lymphoblastic-leukemia-a11624https://doaj.org/toc/1179-9889Amy MacKenzie, Margaret KasnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USAAbstract: The standard treatment of adult-onset acute lymphoblastic leukemia (ALL) is based on trials conducted 20&ndash;25 years ago and has remained largely unchanged since that time. Treatments are lengthy and have been extrapolated from successful pediatric regimens. However, adult disease is cytogenetically different from pediatric disease. Adults often have comorbidities that make completing treatment challenging, and outcomes subsequently suffer. Advances in the understanding of cytogenetics and molecular biology have led to the identification of prognostic factors, as well as offering fertile ground for the development of new therapeutics. The current research in ALL focuses on the development of monoclonal antibodies and small molecule inhibitors, as well as increasing sensitivity in monitoring minimal residual disease, improving upon current chemotherapy, and improving stem cell transplantation. This monograph reviews the current standard of care for adult ALL and the innovations in clinical investigation that aim to improve the future for adults who suffer from this disease. The adult population is in great need of similar advances and stands to benefit tremendously from the research discussed in this review. The challenges of sustainable remission and reduced morbidity and mortality in treatment remain to be surmounted. The aggressive efforts of current clinical trials that are investigating novel therapies both alone and with standard treatment offer hope for adults that is slowly beginning to be realized.Keywords: adult acute lymphoblastic leukemia, Philadelphia chromosome, monoclonal antibodies, molecular pathwaysMacKenzie AKasner MDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 145-158 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 MacKenzie A Kasner M Therapeutic developments in acute lymphoblastic leukemia
description	Amy MacKenzie, Margaret KasnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USAAbstract: The standard treatment of adult-onset acute lymphoblastic leukemia (ALL) is based on trials conducted 20&ndash;25 years ago and has remained largely unchanged since that time. Treatments are lengthy and have been extrapolated from successful pediatric regimens. However, adult disease is cytogenetically different from pediatric disease. Adults often have comorbidities that make completing treatment challenging, and outcomes subsequently suffer. Advances in the understanding of cytogenetics and molecular biology have led to the identification of prognostic factors, as well as offering fertile ground for the development of new therapeutics. The current research in ALL focuses on the development of monoclonal antibodies and small molecule inhibitors, as well as increasing sensitivity in monitoring minimal residual disease, improving upon current chemotherapy, and improving stem cell transplantation. This monograph reviews the current standard of care for adult ALL and the innovations in clinical investigation that aim to improve the future for adults who suffer from this disease. The adult population is in great need of similar advances and stands to benefit tremendously from the research discussed in this review. The challenges of sustainable remission and reduced morbidity and mortality in treatment remain to be surmounted. The aggressive efforts of current clinical trials that are investigating novel therapies both alone and with standard treatment offer hope for adults that is slowly beginning to be realized.Keywords: adult acute lymphoblastic leukemia, Philadelphia chromosome, monoclonal antibodies, molecular pathways
format	article
author	MacKenzie A Kasner M
author_facet	MacKenzie A Kasner M
author_sort	MacKenzie A
title	Therapeutic developments in acute lymphoblastic leukemia
title_short	Therapeutic developments in acute lymphoblastic leukemia
title_full	Therapeutic developments in acute lymphoblastic leukemia
title_fullStr	Therapeutic developments in acute lymphoblastic leukemia
title_full_unstemmed	Therapeutic developments in acute lymphoblastic leukemia
title_sort	therapeutic developments in acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/f7dd595bd9334542af83b920fe83b3ab
work_keys_str_mv	AT mackenziea therapeuticdevelopmentsinacutelymphoblasticleukemia AT kasnerm therapeuticdevelopmentsinacutelymphoblasticleukemia
_version_	1718400389814943744

Therapeutic developments in acute lymphoblastic leukemia

Ejemplares similares